{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-034242","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2025-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.418166+00:00","generated_at":"2026-05-17T07:29:05.255899+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Galectin Therapeutics updates corporate presentation; no new specific data in filing excerpt","bullets":["Presentation dated September 2025 covers pipeline and strategy, but no clinical or financial figures are disclosed in the filing text.","Lead candidate belapectin (galectin-3 inhibitor) is highlighted without new trial results or milestones.","Forward-looking statements caution that actual results may differ materially from projections.","Investors should review the full presentation on the company's website for material updates."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-034242","json":"https://secwatch.observer/filing/0001140361-25-034242.json","markdown":"https://secwatch.observer/filing/0001140361-25-034242.md","text":"https://secwatch.observer/filing/0001140361-25-034242.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125034242/0001140361-25-034242-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125034242/ef20055150_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:29:05.255899+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}